Non–Small Cell Lung Cancer Coverage from Every Angle
Editor:
Gregory J. Riely, MD, PhD
Advertisement
Advertisement

News

AACR 2025: Divarasib Plus Migoprotafib Combination Treatment KRAS G12C-Positive NSCLC
AACR 2025: Updated Results From HORIZON-Lung
FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC
Several Rare, Actionable EGFR Mutations Overlooked With Multigene Testing
Increased Risks of Lung Cancer Among Those With Higher Genetic Sensitivity to Stress
Mobocertinib vs Chemotherapy in EGFR Exon 20 Insertion–Positive Advanced NSCLC
Advanced NSCLC: Targeting the CD73/Adenosine Pathway
Role of Bilateral Mediastinal Lymphadenectomy in Stage I NSCLC
Case Report: A Nonsmoking Welder Develops Rare NSCLC
How Useful Is CT Imaging in Identifying Atherosclerosis in Patients With Lung Cancer?
Using Gene-Edited Stem Cells and Oncolytic Viruses to Treat Lung Cancer Brain Metastases
Could Computable Phenotypes Determine Eligibility for Lung Cancer Screening?
Comparing Operative Approaches in the Management of NSCLC
Can ORACLE Predict Survival and Chemotherapy Response in Lung Adenocarcinoma?
NSCLC: Another Cancer in Which CD47 Expression Makes a Difference
Study Finds Potential Clinical Use of EGFR TKIs in BRAF Class 3–Mutated NSCLC
Can Deep Learning Models Predict Immunotherapy Response in Advanced NSCLC?
Researchers Look at Clinical Trial Eligibility Criteria for Those With Metastatic NSCLC
Surgery and Survival in Early-Stage Lung Cancer: Learning From Real-World Data
Combination of Chemotherapy, Immunotherapy, and Radiotherapy for NSCLC With Brain Metastases
EGFR-Mutant NSCLC: Weight Loss, Osimertinib, and Survival
Investigational Oral Therapy Receives Fast Track Designation for KRAS G12C–Mutated NSCLC
Study Plans to Evaluate Adjuvant Osimertinib in Resected EGFR-Mutated NSCLC
‘Knowing the Type of KRAS Mutation Is Critical’ in Managing KRAS-Mutant NSCLC
Use of Osimertinib and Cardiac Events: Is There a Connection?
Are Sodium Levels a Prognostic Indicator of Survival in Metastatic NSCLC?
Can Comprehensive Genome Profiling Determine the Right Treatment for Patients With NSCLC?
Can Selinexor Plus Docetaxel Improve Outcomes in Advanced KRAS-Mutant NSCLC?
FDA Approval: ALK Inhibitor Ensartinib for ALK-Positive Locally Advanced or Metastatic NSCLC
Adding Radiotherapy to TKIs in Metastatic EGFR-Mutated NSCLC Population
Combination of Sintilimab and Nab-Paclitaxel in Advanced Squamous NSCLC
Copyright © 2025 National Comprehensive Cancer Network, All Rights Reserved
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.